Inhibition of the autocrine IL-6-JAK2-STAT3-calprotectin axis as targeted therapy for HR-/HER2+ breast cancers.

Genes Dev · 2015 · PMC4536311 · PMID 26227964

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a strong trendno p-value reported

HR + /HER2 + tumors preferentially recur in bones, while there is a strong trend for more visceral metastases in the HR − /HER2 + cancers ( Paluch-Shimon et al. 2009 ; Vaz-Luis et al. 2012 ).

also in 5,725 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.